Skip to main content

Pharmacokinetics of long-lasting, high-dose dexmedetomidine infusions in critically ill patients

Introduction

The aim of this study was to characterize the pharmaco-kinetics of long dexmedetomidine (dexmed) infusions and assess the dose linearity of high doses.

Methods

Dexmed was infused to critically ill intensive care patients for 12 hours using a constant infusion rate determined by the prestudy dose of propofol or midazolam. After the first 12 hours, the infusion rate of dexmed was titrated between 0.1 and 2.5 μg/kg/hour using prefixed levels to maintain sedation in range of 0 to -3 on the Richmond Agitation-Sedation Scale (RASS). Dexmed was continued as long as required to a maximum of 14 days. Safety and tolerability were assessed by adverse events, heart rate, blood pressure, ECG and laboratory tests.

Results

Dexmed concentration profiles of the 13 patients during the infusion and 48-hour follow-up are depicted in Figure 1. The geometric mean values (CV%) for length of infusion, dexmed half-time, clearance and volume of distribution (elimination) were 91 hours (117%), 3.7 hours (38%), 41 l/hour (47%) and 223 l (35%), respectively. There was a linear relationship (r2 = 0.95; P < 0.001) between the areas under the dexmed plasma concentration-time curves and cumulative doses of dexmed. All but one patient needed propofol to keep the RASS value in the target zone. The most common adverse events were tachycardia, hypotension and hypertension.

Figure 1
figure1

Dexmedetomidine concentration profiles of the 13 patients.

Conclusions

The pharmacokinetics of dexmed was linear up to the dose of 2.5 μg/kg/hour. Despite the high dose and long-lasting infusions, safety findings were as expected for dexmed and the patient population.

Author information

Affiliations

Authors

Corresponding author

Correspondence to T Iirola.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Iirola, T., Aantaa, R., Laitio, R. et al. Pharmacokinetics of long-lasting, high-dose dexmedetomidine infusions in critically ill patients. Crit Care 15, P353 (2011). https://doi.org/10.1186/cc9773

Download citation

Keywords

  • Midazolam
  • Prefix
  • Infusion Rate
  • Dexmedetomidine
  • Intensive Care Patient